Alligator Bioscience: ATOR-1017 pre-clinical data support a best-in-class 4-1BB antibody profile
– Unique binding profile and cross-linking properties – Oral presentation at Protein Engineering Summit in Boston, ...
Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on 26 April 2018
Lund, Sweden, 26 April 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...
Alligator Bioscience AB Interim Report January-March 2018
Positive preclinical data for ATOR-1015 "Data provide strong support for our claims that ATOR-1015 is a next generation bispecific CTLA- ...
Save the date: Alligator Bioscience to host Capital Markets Day in Stockholm on 29 May 2018
Lund, Sweden, 18 April 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...
Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation
Lund, Sweden, 17 April 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...
Alligator Bioscience presents at the H.C. Wainwright Annual Global Life Sciences Conference
Lund, Sweden, 5 April – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals fo ...
Alligator Bioscience’s Annual Report 2017 published
Lund, Sweden, 22 March – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals f ...
Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ)
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator Bioscience AB Full Year Report 2017
The Janssen collaboration continues, milestone payment of 6 MUSD triggered Significant events, October-December • Alligator Bioscience recor ...